SC 139471

Edinburgh Pharmaceutical Processes Limited

Abbreviated Balance Sheet as at 31 May 2003

	2003		2002	
lotes	£	£	£	£
2		35,648		47,353
	100,138		115,148	
	391		521	
	100,529		115,669	
	(134,518)		(146,137)	
		(33,989)		(30,468)
		1,659		16,885
		722222		
3		100		100
				16,785
		1,659		16,885
	lotes 2	100,138 391 100,529 (134,518)	2 35,648	2 35,648 100,138 115,148 391 521 100,529 115,669 (134,518) (146,137) (33,989) 1,659 100 1,559

The director's statements required by Section 249B(4) are shown on the following page which forms part of this Balance Sheet.

The notes on pages 3 to 4 form an integral part of these financial statements.



Page I

Edinburgh Pharmaceutical Processes Limited

Abbreviated Balance Sheet (continued)

Director's statements required by Section 249B(4) for the year ended 31 May 2003

In approving these abbreviated accounts as director of the company I hereby confirm:

- (a) that for the year stated above the company was entitled to the exemption conferred by Section 249A(I) of the Companies Act 1985:
- (b) that no notice has been deposited at the registered office of the company pursuant to Section 249B(2) requesting that an audit be conducted for the year ended 31 May 2003 and
- (c) that I acknowledge my responsibilities for:

Styden Newlords

- (1) ensuring that the company keeps accounting records which comply with Section 221, and
- (2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Section 226 and which otherwise comply with the provisions of the Companies Act relating to financial statements, so far as applicable to the company.

These abbreviated accounts are prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies.

The abbreviated accounts were approved by the Board on 23 November 2004 and signed on its behalf by

Dr S F Newlands

Director

Edinburgh Pharmaceutical Processes Limited

Notes to the Abbreviated Accounts for the year ended 31 May 2003

1. Accounting Policies

1.1. Accounting convention

The accounts are prepared under the historical cost convention.

The company has taken advantage of the exemption in FRS1 from the requirement to produce a cashflow statement because it is a small company.

1.2. Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

1.3. Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Plant and machinery

25% reducing balance

Fixtures, fittings

and equipment

25% reducing balance

1.4. Pensions

The pension costs charged in the financial statements represent the contribution payable by the company during the year. The regular cost of providing retirement pensions and related benefits is charged to the profit and loss account over the employees' service lives on the basis of a constant percentage of earnings.

2.	Fixed assets	Tangible	
		fixed	
		assets	
		£	
	Cost		
	At I June 2002	113,828	
	Additions	188	
	At 31 May 2003	114,016	
	Depreciation		
	At I June 2002	66,475	
	Charge for year	11,893	
	At 3! May 2003	78,368	
	Net book values		
	At 31 May 2003	35,648	
	At 31 May 2002	47,353	

Edinburgh Pharmaceutical Processes Limited

Notes to the Abbreviated Accounts for the year ended 31 May 2003

3.	Share capital	2003	2002
		£	£
	Authorised equity		
	2 Ordinary shares of 50 pounds each	100	100
	Allotted, called up and fully paid equity		
	2 Ordinary shares of 50 pounds each	100	100